MicuRx Pharmaceuticals, Inc.
  • About MicuRx
    • Our company
    • Our Team
    • Vision & mission
    • History
    • Contact Us
  • Scientific research
    • Antibiotic Resistance
    • Kidney Disease
    • MicuRx R&D
    • Publications
  • Pipeline
  • Newsroom
    • Corporate news
  • Careers
  • Contact Us
  • 中
  • In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis

    Time:2018-05-13  /  View:654 times
    Prev: Single- and Multiple-Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I Versus Linezolid in Healthy Adult Subjects
    Next: Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.
    Back

    Copyright © 2025 All Rights Reserved MicuRx

    Medical Representative Recordation Platform 沪ICP备12020812号

    MicuRx Pharmaceuticals, Inc.